Please login to the form below

Not currently logged in
Email:
Password:

study

This page shows the latest study news and features for those working in and with pharma, biotech and healthcare.

AZ’s MYSTIC survival data is in – and it’s a bust

AZ’s MYSTIC survival data is in – and it’s a bust

it has confirmed the study is a failure. ... There’s no doubt that overall the study is a big disappointment, and will allow Merck &Co’s rival PD-1 inhibitor Keytruda (pembrolizumab) to maintain its fierce grip on the

Latest news

  • Roche builds on Immunocore ImmTAC deal Roche builds on Immunocore ImmTAC deal

    Immuncore's lead in-house project, IMCgp100, is in pivotal studies for uveal melanoma, and encouraging phase 1 data was presented at ASCO earlier this year.

  • Roche pulls EU Tecentriq/Avastin filing in kidney cancer Roche pulls EU Tecentriq/Avastin filing in kidney cancer

    Roche was seeking approval for Tecentriq and Avastin as a first-line treatment for advanced or metastatic RCC based on the results of the phase 2 IMmotion151 study, which showed that ... line use of the pair in non-small cell lung cancer (NSCLC) based on

  • UniQure skyrockets on haemophilia B gene therapy data UniQure skyrockets on haemophilia B gene therapy data

    It recently recruited the first patient for that study. HOPE-B will recruit around 50 adults with moderately severe or severe haemophilia B who will receive a single dose of ... The primary endpoint of the study will be the Factor IX activity level,

  • Orphan drugs from Biogen and Amicus win UK Prix Galien Orphan drugs from Biogen and Amicus win UK Prix Galien

    Sir Michael Rawlins commented: “Clinical studies show powerful evidence of improved survival alongside patients achieving and/or maintaining developmental motor milestones closer to those expected for their age and inconsistent with

  • Duchenne UK backs Evox dystrophin delivery project Duchenne UK backs Evox dystrophin delivery project

    Duchenne UK backs Evox dystrophin delivery project. Funding will drive preclinical studies on dystrophin-bearing exosomes. ... The funding round will help Evox carry out preclinical studies on dystrophin-bearing exosomes, to see if the approach can be an

More from news
Approximately 5 fully matching, plus 1,434 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    A phase 2 study in the condition Geographic Atrophy (GA), which is the advanced stage of dry age-related macular degeneration, will begin in 2019. ... The previous licensing deal was for exclusive global rights to the phase 1‐ ready RSV compound,

  • Behaviour change: what is the buzz all about? Behaviour change: what is the buzz all about?

    Take an example from another highly evidence-based profession: the judiciary. A study has shown that the decisions of US Supreme Court justices appointed by Republican presidents were significantly more conservative ... Although the application of

  • Three steps forward, four steps back Three steps forward, four steps back

    However, a recent study by the Commonwealth Fund affirmed that only 43% (Apple iTunes store) and 27% (Google Play store) of healthcare apps energised patient engagement.

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinson’s disease trials

    The design of such neuroprotective studies may benefit from the lessons learned in studies in the most common neurodegenerative disease, Alzheimer’s. ... In contrast to most other drug trials, the study subjects would not see any effect, even if they

  • Nudge-nudge, think-think Nudge-nudge, think-think

    The power of achieving the triad of capability, opportunity and peer endorsement is evidenced by a recent study into how to avoid retrograde outcomes when switching patients from biologics to biosimilars. ... The study found that the combination of

More from intelligence
Approximately 6 fully matching, plus 348 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 54 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 33 fully matching, plus 570 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics